Neurocrine Biosciences Selected Ruder Finn for US Account
The pharmaceutical company tapped the agency to lead its communications following a competitive review process.
Updated on Sept. 29, 2026 in Advertising
Live Poll
Do you trust large corporations more when they handle their own communications in-house?
Neurocrine Biosciences has appointed Ruder Finn as its US communications agency of record. The selection follows a competitive review and covers corporate reputation, digital work, and product communications.
Why it matters
The partnership is designed to support the ongoing operations of the company's neuropsychiatry and endocrinology divisions. By centralizing these functions, the pharmaceutical firm aims to refine its corporate narrative and creative strategy.
Neurocrine Biosciences reported total revenue of $2.86 billion in 2025. The firm has now moved to align this commercial scale with a new agency partner to manage its diverse business portfolio.
The players
Neurocrine Biosciences
This San Diego-based pharmaceutical company specializes in developing treatments for neurological and endocrine-related diseases.
Ruder Finn
This global communications agency provides strategic services including corporate reputation management and digital marketing for large-scale enterprise clients.
Kelley Yoder
She serves as the senior counsel and relationship lead for the account at Ruder Finn.
Christie Anbar
She co-leads the account and oversees the product strategy for the client.
Kate Hardin
She leads the corporate communications department at the pharmaceutical company.
The details
Ruder Finn will oversee product and pipeline communications alongside digital and creative operations. The account work spans across the San Diego-based pharmaceutical firm's specialized neuropsychiatry and endocrinology business segments.
Timeline
Neurocrine Biosciences generated $2.86 billion in total revenue during 2025.
Ruder Finn officially began its account engagement in July 2026.
The official announcement of the agency of record status occurred on September 29, 2026.
Market Landscape
This move follows the industry trend of pharmaceutical firms consolidating diverse communications needs under a single agency to unify corporate and product-level messaging. It positions the agency to manage the complex regulatory and reputational requirements inherent in the neuropsychiatry sector.
The transition to a new agency is unlikely to change daily product pricing or availability for current patients. However, the move suggests that consumers may see refined corporate messaging and digital outreach regarding the company's therapeutic pipelines in the near future.
The takeaway
Large pharmaceutical firms often consolidate communication agencies to streamline how they talk about complex medical pipelines and corporate achievements. Patients should monitor official company channels for clearer information on new developments as these integrated communication strategies take hold.
Further reading
For more on shifts in the industry, see our coverage of Advertising.
Source note: This article includes information reported by PRovoke Media.
Live Poll
Do you trust large corporations more when they handle their own communications in-house?
